Acc Pathway Finds Empagliflozin Preferred Sglt2 Therapy For Patients With Type 2 Diabetes Ascvd | Latest News RSS feed

Acc Pathway Finds Empagliflozin Preferred Sglt2 Therapy For Patients With Type 2 Diabetes Ascvd - Latest News


ACC Pathway Finds Empagliflozin "Preferred" SGLT2 Therapy for Patients With Type 2 Diabetes, ASCVD

The authors noted that until recently, medications to control blood glucose were not expected to offer any benefit in helping patients avoid cardiovascular events. A new American College of Cardiology ... read more

Clear Consensus—Treat Cardiovascular Disease Concurrent with Diabetes

Clinicians caring for patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) now have more guidance in recommending the best treatment to manage both conditions. 1 The ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us